Novo Nordisk's CFO: Our patent for semaglutide in India will expire in a few months; we expect to face more generic competition in the Indian weight loss drug market.

2026-02-04

Novo Nordisk's CFO: Our patent for semaglutide in India will expire in a few months; we expect to face more generic competition in the Indian weight loss drug market.